Virios Therapeutics, Inc. (VIRI)

$0.445

+0.14 (+43.55%)
Rating:
Recommendation:
-
Symbol VIRI
Price $0.445
Beta 1.845
Volume Avg. 0.39M
Market Cap 8.157M
Shares () -
52 Week Range 0.219-9.111
1y Target Est -
DCF Unlevered VIRI DCF ->
DCF Levered VIRI LDCF ->
ROE -142.56% Strong Sell
ROA -146.33% Strong Sell
Operating Margin -
Debt / Equity 14.24% Neutral
P/E -0.40 Neutral
P/B 0.67 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest VIRI news


Mr. Gregory Duncan
Healthcare
Biotechnology
NASDAQ Capital Market

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.